Exploration of peripheral blood immune rejection and tolerance biomarkers after liver transplantation

Status

Recruiting

Phases

Early Phase 1

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR2300070974

Enrollment

Unknown

Registered

2023-04-27

Start date

2023-05-01

Completion date

Unknown

Last updated

2023-06-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Liver transplantation

Interventions

Adult:N/A

Children:N/A

Eligibility

Sex/Gender

All

Age

No minimum to 70 Years

Inclusion criteria

Inclusion criteria: (1) Age at liver transplantation: 18 years in the adult group; (2) Use of the same anti-rejection regimen and with prophylactic, empirical anti-infection regimens within each group for children and adults; (3) No significant bacterial, viral or fungal infection-related symptoms, body fluid biochemistry and etiological evidence during the time interval of peripheral blood collection.

Exclusion criteria

Exclusion criteria: (1) Patients with inconsistent anti-rejection regimens, or mutations in genes related to tacrolimus metabolism, or postoperative fluctuations in blood levels outside the expected range (2) Patients with other clear evidence of preoperative viral infection (e.g. hepatitis C virus, cytomegalovirus) (3) Other immune system disorders, secondary liver transplantation, combined organ transplantation, ABO blood group incompatibility, or significant postoperative vascular or biliary complications

Design outcomes

Primary

Measure	Time frame
Banff score for liver puncture biopsy;	—

Secondary

Measure	Time frame
dd-cfDNA;Single cell sequencing of peripheral blood mononuclear cells;	—

Countries

China

Contacts

Public ContactYang Jaying

West China Hospital,Sichuan Universit

doctoryjy@scu.edu.cn+86 18980602047

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026